CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas

Authors: Bhatt G, Maddocks K Christian B
Published in: Curr Hematol Malig Rep. 2016 Sep 9.

Abstract
Evolution of cancer therapeutics has resulted in the development of agents with varying mechanisms of selective target inhibition.

One such therapeutic approach is utilizing antibody-drug conjugates (ADCs), the combination of a cytotoxic agent linked with a monoclonal antibody, to achieve localization of the target and internalization of the cytotoxic agent in order to maximize efficacy with fewer toxicities.

MabPlex
ADC Bio
Lonza
 

This review focuses on CD30 as a therapeutic target and the development and clinical activity of the ADC brentuximab vedotin in Hodgkin lymphoma (HL) and other B cell lymphomas.


Author affiliation: The Ohio State University James Comprehensive Cancer Center, 420 West 10th Avenue, A348 Starling Loving Hall, Columbus, OH, 43210, USA.

Featured Image: Micrograph of Hodgkin lymphoma. Lymph node FNA specimen. Field stain. The micrograph shows a mixture of cells common in Hodgkin Lymphoma, including Eosinophils, Reed-Sternberg cells, Plasma cells and Histiocytes. Feature image Courtesy: Nephron. This file is licensed under the Creative Commons Attribution-Share Alike 3.0 Unported license. CC BY-SA 3.0

Previous articleOutsmarting Cancer – From the War on Cancer to the Cancer Moonshot
Next articlePhase I Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia Initiated
ADC Review
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) launched in 2013, is designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians/physicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers. The Journal’s content includes peer reviewed research, commentaries, news features, discussions, editorials and blogs on topics relevant to a broad international readership. The Journal also offers a knowledge center (called ADC University) offering the latest and most relevant information about Antibody-drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments. The purpose of the Journal is to present this information in an understandable and a useful format for all stakeholders.